RDP58

RDP58 is an investigational synthetic decapeptide (10-amino acid peptide) designed as a multi-cytokine inhibitor for the treatment of inflammatory conditions. Developed by SangStat Medical Corporation and later acquired by Genzyme, the peptide was engineered through rational drug design to suppress the production of several key pro-inflammatory cytokines, including tumor necrosis factor-alpha (TNF-α), interferon-gamma (IFN-γ), interleukin-2 (IL-2), interleukin-6 (IL-6), and interleukin-12 (IL-12). Additionally, RDP58 has been shown to up-regulate the expression of heme oxygenase-1 (HO-1), an enzyme with significant anti-inflammatory and cytoprotective effects. Its mechanism of action involves the disruption of cellular signal transduction pathways associated with Toll-like receptors (TLRs) and the TNF receptor family. RDP58 was evaluated in Phase II clinical trials for inflammatory bowel diseases, such as Crohn's disease and ulcerative colitis, and in Phase I trials for chemotherapy-induced diarrhea. Development of the compound was discontinued following Genzyme's acquisition of SangStat in 2003.

Other names

RDP-58RDP58RDP 58